Clarus Wealth Advisors Decreases Stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Clarus Wealth Advisors lowered its holdings in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 7.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,073 shares of the financial services provider’s stock after selling 519 shares during the quarter. Clarus Wealth Advisors’ holdings in iShares Nasdaq Biotechnology ETF were worth $851,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. increased its position in iShares Nasdaq Biotechnology ETF by 4.2% during the first quarter. Sumitomo Mitsui Financial Group Inc. now owns 4,917 shares of the financial services provider’s stock valued at $530,000 after acquiring an additional 198 shares during the last quarter. Quattro Financial Advisors LLC increased its position in iShares Nasdaq Biotechnology ETF by 3,765.9% during the first quarter. Quattro Financial Advisors LLC now owns 39,123 shares of the financial services provider’s stock valued at $2,660,000 after acquiring an additional 38,111 shares during the last quarter. Chevy Chase Trust Holdings Inc. purchased a new stake in iShares Nasdaq Biotechnology ETF during the fourth quarter valued at $66,000. Altfest L J & Co. Inc. purchased a new stake in iShares Nasdaq Biotechnology ETF during the first quarter valued at $680,000. Finally, Danda Trouve Investment Management Inc. increased its position in iShares Nasdaq Biotechnology ETF by 5.4% during the first quarter. Danda Trouve Investment Management Inc. now owns 8,003 shares of the financial services provider’s stock valued at $862,000 after acquiring an additional 410 shares during the last quarter. Hedge funds and other institutional investors own 72.33% of the company’s stock.

Separately, ValuEngine cut iShares Nasdaq Biotechnology ETF from a “hold” rating to a “sell” rating in a research report on Thursday, July 2nd.

IBB traded up $0.21 during midday trading on Thursday, reaching $141.02. The company had a trading volume of 10,002 shares, compared to its average volume of 3,623,939. The business has a 50-day moving average of $134.25 and a two-hundred day moving average of $122.00. iShares Nasdaq Biotechnology ETF has a 1 year low of $92.15 and a 1 year high of $142.33.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: How can investors benefit from after-hours trading?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.